Aug 4 (Reuters) - Sensei Biotherapeutics Inc SNSE.O :
* SENSEI BIOTHERAPEUTICS REPORTS SECOND QUARTER 2021 RESULTS
AND
HIGHLIGHTS RECENT IN VIVO DATA FROM SNS-VISTA PROGRAM
* SENSEI BIOTHERAPEUTICS - PLANS TO SELECT A LEAD SNS-VISTA
CANDIDATE AND INITIATE IND-ENABLING STUDIES BY YEAR-END 2021
* SENSEI BIOTHERAPEUTICS - SNS-401-NG ON TRACK TO START
IND-ENABLING STUDIES IN SECOND HALF OF 2022
* SENSEI BIOTHERAPEUTICS - EXPECTS CURRENT CASH BALANCE TO
FUND
OPERATIONS AT LEAST INTO FIRST HALF OF 2024
* SENSEI BIOTHERAPEUTICS - QTRLY NET LOSS PER SHARE $0.32
Source text for Eikon: ID:nGNX4Qv4m4
Further company coverage: SNSE.O
((Reuters.Briefs@thomsonreuters.com;))